Imipenem resistance of Pseudomonas in pneumonia: A systematic literature review

BMC Pulmonary Medicine

Volumn 10, Issue , 2010, Pages

  Zilberberg, Marya D ^a,b   Chen, Joyce ^c   Mody, Samir H ^c   Ramsey, Andrew M ^b   Shorr, Andrew F ^d  

^a UNIVERSITY OF MASSACHUSETTS   (United States)

^b EviMed Research Group LLC   (United States)

^c Ortho McNeil Pharmaceutical Incorporated   (United States)

^d WASHINGTON HOSPITAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AZTREONAM; BETA LACTAM ANTIBIOTIC; CARBAPENEM; CEFTAZIDIME; CEPHALOSPORIN; CIPROFLOXACIN; DORIPENEM; IMIPENEM; LEVOFLOXACIN; MEROPENEM; MONOBACTAM; PENICILLIN G; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SULTAMICILLIN; VANCOMYCIN; ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; CLINICAL TRIAL; CLOSTRIDIUM DIFFICILE INFECTION; COMMUNITY ACQUIRED PNEUMONIA; CONTROLLED CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; ERADICATION THERAPY; HOSPITAL INFECTION; HUMAN; MEDLINE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; OUTCOME ASSESSMENT; PNEUMONIA; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS PNEUMONIA; RANDOMIZED CONTROLLED TRIAL; SYSTEMATIC REVIEW; UNITED STATES; VENTILATOR ASSOCIATED PNEUMONIA; BACTERIAL PNEUMONIA; DRUG EFFECT; MICROBIOLOGY; PSEUDOMONAS INFECTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TREATMENT OUTCOME;

ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, BACTERIAL; HUMANS; IMIPENEM; PNEUMONIA, BACTERIAL; PNEUMONIA, VENTILATOR-ASSOCIATED; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 77956815136     PISSN: None     EISSN: 14712466     Source Type: Journal    
DOI: 10.1186/1471-2466-10-45     Document Type: Article

References (64)

1. Klein E, Smith DL, Laxminarayan R. Hospitalizations and deaths caused by methicillin-resistant Staphylococcus aureus, United States, 1999-2005. Emerg Infect Dis 2007, 13:1840-1846. 2876761, 18258033.
2. Ramsey AM, Zilberberg MD. Secular trends in vancomycin-resistant Enterococcus hospitalization in the US, 2000-2006. Infect Control Hosp Epidemiol 2009, 30:184-6. 10.1086/593956, 19125679.
3. Zilberberg MD, Shorr AF, Kollef MH. Growth and geographic variation in hospitalizations with resistant infections, United States, 2000-2005. Emerg Infect Dis 2008, 14(11):1756-8. 10.3201/eid1411.080337, 2630735, 18976563.
4. National Nosocomial Infections Surveillance (NNIS) System Report. Am J Infect Control 2004, 32:470. 10.1016/j.ajic.2004.10.001, 15573054.
5. Obritsch MD, Fish DN, MacLaren R, Jung R. National surveillance of antimicrobial resistance in Pseudomonas aeruginosa isolates obtained from intensive care unit patients from 1993 to 2002. Antimicrob Agents Chemother 2004, 48:4606-10. 10.1128/AAC.48.12.4606-4610.2004, 529178, 15561832.
6. Hospital-Acquired Pneumonia Guideline Committee of the American Thoracic Society and Infectious Diseases Society of America Guidelines for the management of adults with hospital-acquired pneumonia, ventilator-associated pneumonia, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005, 171:388-416. 10.1164/rccm.200405-644ST, 15699079, Hospital-Acquired Pneumonia Guideline Committee of the American Thoracic Society and Infectious Diseases Society of America.
7. Iregui M, Ward S, Sherman G, Fraser VJ, Kollef MH. Clinical importance of delays in the initiation antibiotic treatment for ventilator-associated pneumonia. Chest 2002, 122:262-268. 10.1378/chest.122.1.262, 12114368.
8. Alvarez-Lerma F. ICU-acquired Pneumonia Study Group. Modification of empiric antibiotic treatment in patients with pneumonia acquired in the intensive care unit. Intensive Care Med 1996, 22:387-394. 10.1007/BF01712153, 8796388.
9. Micek ST, Lloyd AE, Ritchie DJ, Reichley RM, Fraser VJ, Kollef MH. Pseudomonas aeruginosa bloodstream infection: the importance of appropriate initial antimicrobial treatment. Antimicrob Agents Chemother 2005, 49(4):1306-11. 10.1128/AAC.49.4.1306-1311.2005, 1068618, 15793102.
10. Micek ST, Kollef KE, Reichley RM, Roubinian N, Kollef MH. Health case-associated pneumonia annd community-acquired pneumonia: a single-center experience. Antimicrob Agents Chemother 2007, 51(10):3568-73. 10.1128/AAC.00851-07, 2043297, 17682100.
11. Gales A, Jones R, Turnidge J, Rennie R, Ramphal R. Characterization of Pseudomonas aeruginosa Isolates: Occurrence Rates, Antimicrobial Susceptibility Patterns, and Molecular Typing in the Global SENTRY Antimicrobial Surveillance Program, 1997-1999. Clin Infect Dis 2001, 32(Suppl 2):S146-55. 10.1086/320186, 11320454.
12. Hanberger H, Garcia-Rodriguez JA, Gobernado M, Goossens H, Nilsson LE, Struelens MJ. Antibiotic susceptibility among aerobic gram-negative bacilli in intensive care units in 5 European countries. French and Portuguese ICU Study Groups. JAMA 1999, 281(1):67-71. 10.1001/jama.281.1.67, 9892453.
13. Beaucaire G. Evaluation of the efficacy and safety of isepamicin compared with amikacin in the treatment of nosocomial pneumonia and septicaemia. J Chemother 1995, 7(Suppl 2):165-73.
14. Gulberg V, Deibert P, Ochs A, Rossle M, Gerbes AL. Prevention of infectious complications after transjugular intrahepatic portosystemic shunt in cirrhotic patients with a single dose of ceftriaxone. Hepatogastroenterology 1999, 46(26):1126-30.
15. Leblebicioglu H, Rosenthal VD, Arikan OA, Ozgültekin A, Yalcin AN, Koksal I, Usluer G, Sardan YC, Ulusoy S. Turkish Branch of INICC. Device-associated hospital-acquired infection rates in Turkish intensive careunits. Findings of the International Nosocomial Infection Control Consortium (INICC). J Hosp Infect 2007, 65(3):251-7. 10.1016/j.jhin.2006.10.012, 17257710.
16. Gales AC, Sader HHS, Jones RN. Respiratory tract pathogens isolated from patients hospitalized with suspected pneumonia in Latin America: frequency of occurrence and antimicrobial susceptibility profile: results from the SENTRY Antimicrobial Surveillance Program (1997-2000). Diagn Microbiol Infect Dis 2002, 44(3):301-11. 10.1016/S0732-8893(02)00499-6, 12493178.
17. Sader HS, Jones RN, Gales AC, Winokur P, Kugler KC, Pfaller MA, Doern GV. Antimicrobial susceptibility patterns for pathogens isolated from patients in Latin American medical centers with a diagnosis of pneumonia: analysis of results from the SENTRY Antimicrobial Surveillance Program (1997). SENTRY Latin America Study Group. Diagn Microbiol Infect Dis 1998, 32(4):289-301. 10.1016/S0732-8893(98)00124-2, 9934546.
18. García-Sáenz JA, Martín M, Casado A, Pérez-Segura P, Manrique I, Flores L, Macias JA, Cámara JC, Perezagua C, Díaz-Rubio E. Immediate vs. delayed imipenem treatment in cancer patients with profound neutropenia induced by high-dose chemotherapy: results of a randomized study. Rev Esp Quimioter 2002, 15(3):257-63.
19. Torres-Tortosa M, Arrizabalaga J, Villanueva JL, Gálvez J, Leyes M, Valencia ME, Flores J, Peña JM, Pérez-Cecilia E, Quereda C. Grupo Andaluz para el estudio de las Enfermedades Infecciosas; Grupo de estudio de SIDA of the Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica. Prognosis and clinical evaluation of infection caused by Rhodococcus equi in HIV-infected patients: a multicenter study of 67 cases. Chest 2003, 123(6):1970-6. 10.1378/chest.123.6.1970, 12796176.
20. Saballs M, Pujol M, Tubau F, Peña C, Montero A, Domínguez MA, Gudiol F, Ariza J. Rifampicin/imipenem combination in the treatment of carbapenem-resistant Acinetobacter baumannii infections. J Antimicrob Chemother 2006, 58(3):697-700. 10.1093/jac/dkl274, 16895941.
21. Maskin B, Fontán PA, Spinedi EG, Gammella D, Badolati A. Evaluation of endotoxin release and cytokine production induced by antibiotics in patients with Gram-negative nosocomial pneumonia. Crit Care Med 2002, 30(2):349-54. 10.1097/00003246-200202000-00014, 11889308.
22. Feldman C, White H, O'Grady J, Flitcroft A, Briggs A, Richards G. An open, randomised, multi-centre study comparing the safety and efficacy of sitafloxacin and imipenem/cilastatin in the intravenous treatment of hospitalized patients with pneumonia. Int J Antimicrob Agents 2001, 17(3):177-88. 10.1016/S0924-8579(00)00344-7, 11282262.
23. Polk HC, Livingston DH, Fry DE, Malangoni MA, Fabian T, Trachtenberg LS, Gardner SA, Kesterson L, Cheadle WG. Treatment of pneumonia in mechanically ventilated trauma patients. Results of a prospective trial. Arch Surg 1997, 132(10):1086-92.
24. McKindley DS, Boucher BA, Hess MM, Croce MA, Fabian TC. Pharmacokinetics of aztreonam and imipenem in critically ill patients with pneumonia. Pharmacotherapy 1996, 16(5):924-31.
25. Young LS, Sabel AL, Price CS. Epidemiologic, clinical, and economic evaluation of an outbreak of clonal multidrug-resistant Acinetobacter baumannii infection in a surgical intensive care unit. Infect Control Hosp Epidemiol 2007, 28(11):1247-54. 10.1086/521660, 17926275.
26. Corbella X, Ariza J, Ardanuy C, Vuelta M, Tubau F, Sora M, Pujol M, Gudiol F. Efficacy of sulbactam alone and in combination with ampicillin in nosocomial infections caused by multiresistant Acinetobacter baumannii. J Antimicrob Chemother 2000, 45(5):712-3. 10.1093/jac/45.5.712, 10797101.
27. Caldwell JW, Singh S, Johnson RH. Clinical and economic evaluation of subsequent infection following intravenous ciprofloxacin or imipenem therapy in hospitalized patients with severe pneumonia. J Antimicrob Chemother 1999, 43(Suppl A):115.
28. Levin AS, Barone AA, Penço J, Santos MV, Marinho IS, Arruda EA, Manrique EI, Costa SF. Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii. Clin Infect Dis 2002, 35(7):901-2. 10.1086/342570, 12228836.
29. Giamarellos-Bourboulis EJ, Mega A, Pavleas I, Archontoulis N, Rigas K, Vernikos P, Giamarellou H, Thomopoulos G. Impact of carbapenem administration on systemic endotoxemia in patients with severe sepsis and Gram-negative bacteremia. J Chemother 2006, 18(5):502-6.
30. Kuo BI, Fung CP, Liu CY. Meropenem versus imipenem/cilastatin in the treatment of sepsis in Chinese patients. Zhonghua Yi Xue Za Zhi (Taipei) 2000, 63(5):361-7.
31. Cakmakci M, Stern A, Schilling J, Christen D, Roggo A, Geroulanos S. Randomized comparative trial of imipenem/cilastatin versus aminoglycoside plus amoxycillin plus clindamycin in the treatment of severe intra- and post-operative infections. Drugs Exp Clin Res 1993, 19(5):223-7.
32. Link H, Maschmeyer G, Meyer P, Hiddemann W, Stille W, Helmerking M, Adam D. Interventional antimicrobial therapy in febrile neutropenic patients. Study Group of the Paul Ehrlich Society for Chemotherapy. Ann Hematol 1994, 69(5):231-43. 10.1007/BF01700277, 7948312.
33. Egerer G, Goldschmidt H, Salwender H, Hegenbart U, Ehrhard I, Haas R, Ho AD. Efficacy of continuous infusion of ceftazidime for patients with neutropenic fever after high-dose chemotherapy and peripheral blood stem cell transplantation. Int J Antimicrob Agents 2000, 15(2):119-23. 10.1016/S0924-8579(00)00155-2, 10854807.
34. Sakka SG, Glauner AK, Bulitta JB, Kinzig-Schippers M, Pfister W, Drusano GL, Sörgel F. Population pharmacokinetics and pharmacodynamics of continuous versus short-term infusion of imipenem-cilastatin in critically ill patients in a randomized, controlled trial. Antimicrob Agents Chemother 2007, 51(9):3304-10. 10.1128/AAC.01318-06, 2043189, 17620371.
35. Alvarez-Lerma F, Alvarez B, Luque P, Ruiz F, Dominguez-Roldan JM, Quintana E, Sanz-Rodriguez C. ADANN Study Group. Empiric broad-spectrum antibiotic therapy of nosocomial pneumonia in the intensive care unit: a prospective observational study. Crit Care 2006, 10(3):R78. 10.1186/cc4919, 1550932, 16704742.
36. Shorr AF, Susla GB, Kollef MH. Quinolones for treatment of nosocomial pneumonia: a meta-analysis. Clin Infect Dis 2005, 40(Suppl 2):S115-22. 10.1086/426191, 15712099.
37. Tennenberg AM, Davis NB, Wu SC, Kahn J. Pneumonia due to Pseudomonas aeruginosa: the levofloxacin clinical trials experience. Curr Med Res Opin 2006, 22(5):843-50. 10.1185/030079906X100195, 16709306.
38. Snydman D, Fink M, Niederman M, Reinhart H. Treatment of severe pneumonia in hospitalised patients. Results of a multicentre trial comparing i.v. ciprofloxacin with imipenem/cilastatin. Drugs 1995, 49(Suppl 2):439-41. 10.2165/00003495-199500492-00128, 8549393.
39. Chastre J, Wunderink RR, Prokocimer P, Lee M, Kaniga K, Friedland I. Efficacy and safety of intravenous infusion of doripenem versus imipenem in ventilator-associated pneumonia: A multicenter, randomized study. Crit Care Med 2008, 36(4):1089-96. 10.1097/CCM.0b013e3181691b99, 18379232.
40. Yanagihara K, Fukuda Y, Seki M, Izumikawa K, Higashiyama Y, Miyazaki Y, Hirakata Y, Tomono K, Mizuta Y, Tsukamoto K, Kohno S. Clinical comparative study of sulbactam/ampicillin and imipenem/cilastatin in elderly patients with community-acquired pneumonia. Intern Med 2006, 45(17):995-9. 10.2169/internalmedicine.45.1717, 17015999.
41. Schmitt DV, Leitner E, Welte T, Lode H. Piperacillin/tazobactam vs imipenem/cilastatin in the treatment of nosocomial pneumonia--a double blind prospective multicentre study. Infection 2006, 34(3):127-34. 10.1007/s15010-006-5020-0, 16804655.
42. Joshi M, Metzler M, McCarthy M, Olvey S, Kassira W, Cooper A. Comparison of piperacillin/tazobactam and imipenem/cilastatin, both in combination with tobramycin, administered every 6 h for treatment of nosocomial pneumonia. Respir Med 2006, 100(9):1554-65. 10.1016/j.rmed.2006.01.004, 16487695.
43. Romanelli G, Cravarezza P, Pozzi A, Franchino L, Ravizzola G, Zulli R, Donati P, Prometti P, Grassi V. Carbapenems in the treatment of severe community-acquired pneumonia in hospitalized elderly patients: a comparative study against standard therapy. J Chemother 2002, 14(6):609-17.
44. Shorr AF, Zadeikis N, Jackson WL, Ramage AS, Wu SC, Tennenberg AM, Kollef MH. Levofloxacin for treatment of ventilator-associated pneumonia: a subgroup analysis from a randomized trial. Clin Infect Dis 2005, 41(3):414-5. author reply 415-6, 10.1086/431771, 16007546.
45. Zanetti G, Bally F, Greub G, Garbino J, Kinge T, Lew D, Romand JA, Bille J, Aymon D, Stratchounski L, Krawczyk L, Rubinstein E, Schaller MD, Chiolero R, Glauser MP, Cometta A. Cefepime Study Group,. Cefepime versus imipenem-cilastatin for treatment of nosocomial pneumonia in intensive care unit patients: a multicenter, evaluator-blind, prospective, randomized study. Antimicrob Agents Chemother 2003, 47(11):3442-7. 10.1128/AAC.47.11.3442-3447.2003, 253800, 14576100.
46. West M, Boulanger BR, Fogarty C, Tennenberg A, Wiesinger B, Oross M, Wu SC, Fowler C, Morgan N, Kahn JB. Levofloxacin compared with imipenem/cilastatin followed by ciprofloxacin in adult patients with nosocomial pneumonia: a multicenter, prospective, randomized, open-label study. Clin Ther 2003, 25(2):485-506. 10.1016/S0149-2918(03)80091-7, 12749509.
47. Torres A, Bauer TT, León-Gil C, Castillo F, Alvarez-Lerma F, Martínez-Pellús A, Leal-Noval SR, Nadal P, Palomar M, Blanquer J, Ros F. Treatment of severe nosocomial pneumonia: a prospective randomised comparison of intravenous ciprofloxacin with imipenem/cilastatin. Thorax 2000, 55(12):1033-9. 10.1136/thorax.55.12.1033, 1745648, 11083889.
48. Bartoloni A, Strohmeyer M, Corti G, Buonomini MI, Franchino L, Romanelli G, Moretti AM, De Vizzi GB, Petraglia A, Mancini P, Atzeni R, Fogliani V, Giura R, Paradisi F. Multicenter randomized trial comparing meropenem (1.5 g daily) and imipenem/cilastatin (2 g daily) in the hospital treatment of community-acquired pneumonia. Drugs Exp Clin Res 1999, 25(6):243-52.
49. Jaccard C, Troillet N, Harbarth S, Zanetti G, Aymon D, Schneider R, Chiolero R, Ricou B, Romand J, Huber O, Ambrosetti P, Praz G, Lew D, Bille J, Glauser MP, Cometta A. Prospective randomized comparison of imipenem-cilastatin and piperacillin-tazobactam in nosocomial pneumonia or peritonitis. Antimicrob Agents Chemother 1999, 43(3):726.
50. Marra F, Reynolds R, Stiver G, Bryce E, Sleigh K, Frighetto L, MacDougall C, Jewesson P. Piperacillin/tazobactam versus imipenem: a double-blind, randomized formulary feasibility study at a major teaching hospital. Diagn Microbiol Infect Dis 1998, 31(2):355-68. 10.1016/S0732-8893(97)00239-3, 9635910.
51. Ho A, Leung R, Lai CK, Chan TH, Chan CH. Hospitalized patients with community-acquired pneumonia in Hong Kong: a randomized study comparing imipenem/cilastatin and ceftazidime. Respiration 1997, 64(4):303.
52. Raad II, Whimbey EE, Rolston KV, Abi-Said D, Hachem RY, Pandya RG, Ghaddar HM, Karl CL, Bodey GP. A comparison of aztreonam plus vancomycin and imipenem plus vancomycin as initial therapy for febrile neutropenic cancer patients. Cancer 1996, 77(7):1386-94. 10.1002/(SICI)1097-0142(19960401)77:7<1386::AID-CNCR25>3.0.CO;2-X, 8608520.
53. Vic P, Ategbo S, Turck D, Husson MO, Tassin E, Loeuille GA, Deschildre A, Druon D, Elian JC, Arrouet-Lagandre C, Farriaux JP. Tolerance, pharmacokinetics and efficacy of once daily amikacin for treatment of Pseudomonas aeruginosa pulmonary exacerbations in cystic fibrosis patients. Eur J Pediatr 1996, 155(11):948-53. 10.1007/BF02282885, 8911895.
54. Böhme A, Just-Nübling G, Bergmann L, Shah PM, Stille W, Hoelzer D. A randomized study of imipenem compared to cefotaxime plus piperacillin as initial therapy of infections in granulocytopenic patients. Infection 1995, 23(6):349-55. 10.1007/BF01713564, 8655205.
55. Siami GA, Wilkins WT, Bess DT, Christman JW. Comparison of ciprofloxacin with imipenem in the treatment of severe pneumonia in hospitalised geriatric patients. Drugs 1995, 49(Suppl 2):436-8. 10.2165/00003495-199500492-00127, 8549392.
56. Cometta A, Baumgartner JD, Lew D, Zimmerli W, Pittet D, Chopart P, Schaad U, Herter C, Eggimann P, Huber O, Ricou B, Suter P, Auckenthaler R, Chiorela R, Bille J, Scheidegger C, Frei R, Glauser MP. Prospective randomized comparison of imipenem monotherapy with imipenem plus netilmicin for treatment of severe infections in nonneutropenic patients. Antimicrob Agents Chemother. 1994, 38(6):1309-13. 188203, 8092830.
57. Fink MP, Snydman DR, Niederman MS, Leeper KV, Johnson RH, Heard SO, Wunderink RG, Caldwell JW, Schentag JJ, Siami GA, Zameck RL, Haverstock DC, Reinhart HH, Echols RM. Severe Pneumonia Study Group. Treatment of severe pneumonia in hospitalized patients: results of a multicenter, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenem-cilastatin. The Severe Pneumonia Study Group. Antimicrob Agents Chemother 1994, 38(3):547-57. 284496, 8203853.
58. Norrby SR, Finch RG, Glauser M. Monotherapy in serious hospital-acquired infections: a clinical trial of ceftazidime versus imipenem/cilastatin. European Study Group. J Antimicrob Chemother 1993, 31(6):927-37. 10.1093/jac/31.6.927, 8360130.
59. Aloush V, Navon-Venezia S, Seigman-Igra Y, Cabili S, Carmeli Y. Multidrug-resistant Pseudomonas aeruginosa: risk factors and clinical impact. Antimicrob Agents Chemother 2006, 50(1):43-8. 10.1128/AAC.50.1.43-48.2006, 1346794, 16377665.
60. Harris AD, Castro J, Sheppard DC, Carmeli Y, Samore MH. Risk factors for nosocomial candiduria due to Candida glabrata and Candida albicans. Clin Infect Dis 1999, 29(4):926-8. 10.1086/520460, 10589912.
61. Lautenbach E, Weiner MG, Nachamkin I, Bilker WB, Sheridan A, Fishman NO. Imipenem resistance among pseudomonas aeruginosa isolates: risk factors for infection and impact of resistance on clinical and economic outcomes. Infect Control Hosp Epidemiol 2006, 27(9):893-900. 10.1086/507274, 16941312.
62. Spellberg B, Powers JH, Brass EP, Miller LG, Edwards JE. Trends in antimicrobial drug development: implications for the future. Clin Infect Dis 2004, 38(9):1279-86. 10.1086/420937, 15127341.
63. Fox JL. The business of developing antibacterials. Nat Biotechnol 2006, 24(12):1521-8. 10.1038/nbt1206-1521, 17160056.
64. Siempos II, Vardakas KZ, Manta KG, Falagas ME. Carbapenems for the treatment of immunocompetent adult patients with nosocomial pneumonia. Eur Respir J 2007, 29:548-60. 10.1183/09031936.00080206, 17329491.